manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa
manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa
manifestări extrahepatice în hepatitele cronice la copil - Gr.T. Popa
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
167. Quaranta JF, Tran A, Regnier D et al. High prevalence of antibodies to<br />
hepatitis C virus in patients with anti-thyroid autoantibodies. J Hepatol<br />
1993;18:136–8<br />
168. Tran A, Quaranta JF, Banzaken S et al. High prevalence of thyroid<br />
autoantibodies in a prospective series of patients with chronic hepatitis C before<br />
interferon therapy. Hepatology 1993;18:253–7<br />
169. Custro N, Montalto G, Scafidi V et al. Prospective study on thyroid<br />
autoimmunity and dysfunction re<strong>la</strong>ted to chronic hepatitis C and interferon<br />
therapy. J Endocrinol Invest 1997;20:374–80<br />
170. Boadas J, Rodriguez-Espinosa J, Enriquez J et al. Prevalence of thyroid<br />
autoantibodies is not increased in blood donors with hepatitis C virus infection. J<br />
Hepatol 1995;22:611–5<br />
171. Metcalfe RA, Ball G, Kudesia G et al. Failure to find an association<br />
between hepatitis C virus and thyroid autoimmunity. Thyroid 1997;7:421–4<br />
172. Preziati D, LaRosa L, Covini G et al. Autoimmunity and thyroid function<br />
in patients with chronic active hepatitis treated with recombinant interferon-alpha<br />
2a. Eur J Endocrinol 1995;132:587–93<br />
173. Watanabe U, Hashimoto E, Hisamitsu T et al. The risk factor for<br />
development of thyroid disease during interferon alpha therapy for chronic<br />
hepatitis C. Am J Gastroenterol 1994;89:399–4031<br />
174. Marcellin P, Pouteau U, Benhamou JP. Hepatitis C virus infection, alpha<br />
interferon therapy and thyroid dysfunction. J Hepatol 1995;22:364–9<br />
175. Baudin E, Marcellin P, Pouteau M et al. Reversibility of thyroid<br />
dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin<br />
Endocrinol 1993;39:657–61<br />
176. Lisker-Melman M, DiBisceglie A, Usa<strong>la</strong> S et al. Development of thyroid<br />
disease during therapy of chronic viral hepatitis with interferon alpha.<br />
Gastroenterology 1992;102:2155–60<br />
177. Fabris, P.et al, Type 1 diabetes mellitus in patients with chronic hepatitis<br />
C before and after interferon therapy, Alim Pharmacol and Ther, Sept 2003,<br />
18(6):549-558<br />
178. Aytaman A, Bahtiyar G, McFar<strong>la</strong>ne S.I, Interferon-α therapy and Type 1<br />
diabetes mellitus in patients with hepatitis C: pathophysiologic insights, Future<br />
Med, May 2005, 2(3):439-446<br />
179. Plöckinger U; Krüger D; Bergk A; Weich V; Wiedenmann B; Berg T,<br />
Hepatitis-C patients have reduced growth hormone (GH) secretion which<br />
improves during long-term therapy with pegy<strong>la</strong>ted interferon-alpha.Am journal of<br />
gastroenterol 2007;102(12):2724-31<br />
180. Matsumori, A, Matoba Y; Sasayama, S, Di<strong>la</strong>ted Cardiomyopathy<br />
Associated With Hepatitis C Virus Infection, Circu<strong>la</strong>tion, 1995;92:2519-2525<br />
181. Bel<strong>la</strong>ry S, Schiano T, Hartman G et al. Chronic hepatitis with combined<br />
features of autoimmune chronic hepatitis and chronic hepatitis C: favorable<br />
response to prednisone and azathioprine. Ann Intern Med 1995;123:32–4<br />
182. Matsumori, A et al, Hepatitis C Virus Infection and Heart Diseases : A<br />
Multicenter Study in Japan, Jpn Circ J,1998, 62:389-391
Change language